Research dossier
Clinical research on Quercetin
9 trials reviewed across 5 indications.
Strongest evidence
Blood pressure
Mechanism
Quercetin may improve endothelial nitric-oxide signaling and inhibit angiotensin-converting enzyme activity, both upstream of vascular tone.
Meta-analysis of 7 RCTs shows a modest ~3 mmHg systolic reduction, significant only at >500 mg/day. Real but small — relevant as an adjunct in elevated BP, not a primary treatment.
Effect concentrated in hypertensive adults and at ≥500 mg/day. Minimal in normotensives.
Trials cited
Quercetin and blood pressure (meta-analysis of 7 RCTs)
positive · Meta-analysis
Serban et al., 2016, Journal of the American Heart Associationn=587Pooled across 7 trials (587 patients), quercetin lowered systolic BP by ~3.04 mmHg and diastolic by ~2.63 mmHg. The effect was statistically significant only at doses above 500 mg/day. This is a modest, dose-dependent effect, not a substitute for antihypertensive medication.
Effect size is small and the significant signal was confined to the higher-dose subgroup. Most individual trials were short and small.
Anti-inflammatory & senescence
Mechanism
Quercetin scavenges free radicals and downregulates NF-κB-driven cytokine signaling; in the senolytic context it transiently disables pro-survival pathways in senescent cells.
A small but real CRP reduction (−0.33 mg/L) and an RA signal support mild anti-inflammatory activity. The 'senolytic / anti-aging' framing comes from a 9-patient trial where quercetin was paired with prescription dasatinib — not quercetin alone.
Anti-inflammatory effect is small and biomarker-level. Senolytic claims do not transfer to quercetin monotherapy.
Quercetin and C-reactive protein (meta-analysis of 7 RCTs)
positive · Meta-analysis
Mohammadi-Sartang et al., 2017, European Journal of Clinical Nutritionn=522Across 7 trials, quercetin produced a small but significant reduction in CRP (WMD −0.33 mg/L). The signal was strongest at ≥500 mg/day and in people with baseline CRP under 3 mg/L. A measurable anti-inflammatory effect, but a small one.
CRP is a biomarker, not a clinical outcome. A 0.33 mg/L reduction has not been tied to hard endpoints in these trials.
Quercetin in rheumatoid arthritis
positive · RCT
Javadi et al., 2017, Journal of the American College of Nutritionn=50In 50 women with RA, 500 mg/day for 8 weeks improved disease activity, early-morning stiffness, and TNF-α versus placebo. A genuine double-blind signal, but a single small single-center trial in one specific population.
Small, single-center, women only. Needs independent replication before it informs general anti-inflammatory claims.
Dasatinib + quercetin senolytic (first-in-human)
positive · Pilot
Hickson et al., 2019, EBioMedicinen=9A 9-patient open-label first-in-human study showed a short course of dasatinib PLUS quercetin reduced senescent-cell markers. This is the source of much 'quercetin as anti-aging senolytic' hype — but the active partner is a prescription chemotherapy drug, not quercetin alone.
n=9, open-label, and the senolytic effect is driven by the combination with dasatinib (a prescription tyrosine-kinase inhibitor). Says little about quercetin monotherapy. Experimental.
Immune & respiratory infection
Mechanism
Quercetin shows antiviral and immunomodulatory activity in cell culture, including zinc-ionophore effects — but at concentrations far above what oral dosing achieves in human plasma.
The largest immune trial (Heinz 2010, n=1002) was null for respiratory infections. The COVID-era pilots were open-label and tiny. The popular immune positioning is not supported by good controlled evidence.
No reliable benefit in the general population. A fragile post-hoc subgroup (fit adults 40+) is the only positive immune signal.
Quercetin for upper respiratory tract infection
Null · RCT
Heinz et al., 2010, Pharmacological Researchn=1002The largest quercetin immune trial (1,002 adults) found NO benefit on respiratory infection rates overall, or by sex, BMI, or age. Only a post-hoc subgroup of self-rated-fit adults aged 40+ showed reduced severity at 1000 mg/day — a fragile secondary finding.
The headline result is null. The positive finding is a post-hoc subgroup analysis and should be treated as hypothesis-generating, not proof.
Quercetin phytosome in early COVID-19
positive · RCT
Di Pierro et al., 2021, International Journal of General Medicinen=152Industry-fundedA 152-outpatient open-label study reported faster PCR clearance, fewer hospitalizations, and quicker symptom relief with quercetin phytosome added to standard care. Widely cited in COVID-era marketing, but the design makes it weak evidence.
Open-label (no blinding), single research group, and a branded phytosome product (Indena-linked). Open-label designs systematically inflate measured effects. Not confirmatory.
Blood sugar & metabolic
Mechanism
Proposed effects on insulin signaling and glucose uptake are largely mechanistic.
The cleanest T2D trial (Zahedi 2013) found NO improvement in fasting glucose, HbA1c, insulin, or lipids — only a blood-pressure drop. Glycemic claims for quercetin are not supported.
No reliable glycemic benefit shown. Do not position quercetin as a blood-sugar supplement.
Quercetin in women with type 2 diabetes
mixed · RCT
Zahedi et al., 2013, International Journal of Preventive Medicinen=72In 72 women with T2D, quercetin lowered systolic blood pressure but did NOT improve fasting glucose, HbA1c, insulin, or the lipid profile. A useful honesty check: the glycemic claims often attached to quercetin failed in this trial.
Largely null for the primary glycemic endpoints; the only significant change was systolic BP. Often cited selectively for its positive findings.
Exercise & fatigue
Mechanism
Proposed mitochondrial-biogenesis effects (PGC-1α) seen in rodents do not reproduce at human oral doses.
Nieman's repeated athlete trials found no performance benefit and no meaningful blunting of exercise inflammation. The 'natural performance booster' positioning is essentially debunked.
Negligible benefit for exercise performance in trained or untrained adults.
Quercetin in ultramarathon athletes (Western States, Nieman)
Null · RCT
Nieman et al., 2007, Journal of Interferon & Cytokine Researchn=39In ultramarathoners, 1000 mg/day raised plasma quercetin but failed to blunt muscle damage, inflammation, cytokine increases, or hormonal changes. Consistent with the broader Nieman-group record showing no meaningful exercise benefit despite reduced oxidative-stress markers in some trials.
Marketed heavily for athletes; the controlled-trial record for performance and exercise inflammation is consistently null.
4 forms of Quercetin compared
Quercetin (standard / dihydrate)
Poor — low single-digit oral absorption; rapidly conjugated and cleared
Best forGeneral antioxidant / cardiovascular adjunctThe cheapest and most common form, and the reason much in-vitro promise fails to translate. Effective trial doses are ≥500 mg/day precisely because absorption is so low.
Quercefit®
Quercetin phytosome
Higher than standard quercetin (manufacturer claims up to ~20x)
Best forUsed in the COVID-19 pilots and a chronic-fatigue trial where a lower dose was wantedA lecithin/phospholipid-bound form that genuinely improves absorption. Most bioavailability claims are manufacturer-generated; the human outcome data behind it remain thin.
Isoquercetin (quercetin-3-glucoside)
Better absorbed than aglycone quercetin
Best forUsed in some thrombosis and exercise research blendsThe glucoside form is taken up more efficiently in the small intestine than plain quercetin.
Quercetin with bromelain
Bromelain is co-dosed to aid absorption; evidence for the synergy is weak
Best forCommon allergy / sinus stackA popular pairing marketed for allergies, but the absorption-boost claim for bromelain is not well established in humans.
Side effects and drug interactions
Side effects
Headache and tingling
Uncommon · Reported around 1000 mg/day and above
Mild headache and limb tingling have been reported at higher oral doses in some trials.
GI upset
Uncommon
Nausea or stomach discomfort, generally mild and dose-related.
Kidney safety at very high chronic doses
Rare · Chronic intake well above 1000 mg/day
Long-term safety of high-dose quercetin is not well established; theoretical concern about renal effects at supraphysiological intakes.
Drug interactions
Other
CYP3A4 substratescyclosporinemidazolamQuercetin can inhibit CYP3A4 and P-glycoprotein in vitro, potentially altering levels of drugs metabolized by these pathways.
Clinically significant interactions are not well documented at typical doses, but caution is warranted with narrow-therapeutic-index drugs metabolized by CYP3A4.
Additive effect
antihypertensivesAdditive blood-pressure-lowering at doses ≥500 mg/day.
Monitor for additive hypotension if combining with BP medication.
Binds in the gut — separate dosing
fluoroquinolone antibioticsQuercetin may compete at bacterial DNA gyrase / affect fluoroquinolone activity in lab studies; clinical relevance is uncertain.
Separation is a conservative precaution; clinical interaction is not well established.
Other critical caveats
- Plain quercetin is poorly absorbed. Most of the dramatic antiviral and anti-cancer findings come from cell-culture concentrations that oral dosing cannot reach in humans. Treat in-vitro claims with skepticism.
- The 'natural antihistamine' and immune-booster positioning rests on mechanism and in-vitro data, not strong human trials. The largest respiratory-infection RCT (Heinz 2010, n=1002) was null.
- The senolytic / anti-aging story comes from a 9-patient trial pairing quercetin with dasatinib, a prescription chemotherapy drug. It does not validate quercetin taken on its own.
- Blood-pressure and CRP benefits are real but small, and only appear at ≥500 mg/day — mostly in people who are already elevated.
Frequently asked
Does quercetin actually help with allergies?
The 'natural antihistamine' claim comes mostly from cell-culture studies showing mast-cell stabilization. Human allergic-rhinitis trials are few, small, and methodologically weak. There may be a mild effect, but the evidence does not support strong claims. If allergies are the goal, standard antihistamines have far stronger evidence.Will quercetin boost my immune system or prevent colds?
The largest trial — 1,002 adults over 12 weeks — found no reduction in respiratory infections overall. The COVID-19 pilots were tiny and open-label, which inflates measured effects. The immune positioning is not backed by good controlled evidence.How much quercetin should I take, and what form?
Trials that showed any effect used 500–1000 mg/day, largely because plain quercetin is so poorly absorbed. Phytosome (Quercefit) and isoquercetin are better-absorbed forms, though the human outcome data behind them are still thin. There is no established RDA or upper limit.Is quercetin a senolytic / anti-aging supplement?
That idea traces to a 9-person study where quercetin was combined with dasatinib, a prescription cancer drug. The senolytic effect was driven by the combination, not by quercetin alone. Taking quercetin by itself has not been shown to clear senescent cells in humans.Does quercetin improve exercise performance?
Multiple trials from the leading research group found no performance benefit and no meaningful reduction in exercise-induced inflammation. The athletic positioning is essentially unsupported.
References
- 01Examine.com — Quercetin
- 02Serban et al., 2016 — Quercetin and blood pressure meta-analysis (JAHA)
- 03Mohammadi-Sartang et al., 2017 — Quercetin and CRP meta-analysis (Eur J Clin Nutr)
- 04Heinz et al., 2010 — Quercetin and URTI RCT (Pharmacological Research)
- 05Hickson et al., 2019 — Dasatinib + quercetin senolytic first-in-human (EBioMedicine)
Last reviewed2026-05-24